← Back to Screener
Anavex Life Sciences (AVXL)
Price$3.65
Favorite Metrics
Price vs S&P 500 (26W)-69.48%
Price vs S&P 500 (4W)-19.84%
Market Capitalization$338.25M
All Metrics
Book Value / Share (Quarterly)$1.37
P/TBV (Annual)4.07x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)-1.89%
EPS (TTM)$-0.46
10-Day Avg Trading Volume1.10M
EPS Excl Extra (TTM)$-0.46
EPS (Annual)$-0.54
ROI (Annual)-48.89%
Cash / Share (Quarterly)$1.42
ROA (Last FY)-44.67%
EBITD / Share (TTM)$-0.51
ROE (5Y Avg)-35.39%
Cash Flow / Share (Annual)$-0.45
P/B Ratio2.67x
P/B Ratio (Quarterly)2.51x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-155.83x
ROA (TTM)-35.01%
EPS Incl Extra (Annual)$-0.54
Current Ratio (Annual)11.60x
Quick Ratio (Quarterly)20.81x
3-Month Avg Trading Volume1.68M
52-Week Price Return-58.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.80
52-Week High$13.99
EPS Excl Extra (Annual)$-0.54
Tangible BV CAGR (5Y)42.50%
26-Week Price Return-60.73%
Quick Ratio (Annual)11.56x
13-Week Price Return-24.48%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.87x
Enterprise Value$206.503
Book Value / Share Growth (5Y)20.07%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.18
3-Month Return Std Dev93.24%
Net Income / Employee (TTM)$-1
ROE (Last FY)-48.89%
Net Interest Coverage (Annual)-29.59x
EPS Basic Excl Extra (Annual)$-0.54
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.46
ROI (TTM)-38.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.83
Price vs S&P 500 (52W)-93.92%
Year-to-Date Return2.25%
5-Day Price Return17.04%
EPS Normalized (Annual)$-0.54
ROA (5Y Avg)-32.41%
Month-to-Date Return18.57%
EBITD / Share (Annual)$-0.59
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-35.39%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.46
P/TBV (Quarterly)3.95x
P/B Ratio (Annual)8.06x
Book Value / Share (Annual)$1.09
Price vs S&P 500 (13W)-27.35%
Beta1.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-38.76%
52-Week Low$2.61
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AVXLAnavex Life Sciences | — | — | — | — | $3.65 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing precision medicine treatments for central nervous system disorders with high unmet need. The company uses genomic biomarker analysis to advance programs targeting Alzheimer's disease, Parkinson's disease, schizophrenia, and rare neurological conditions including Rett syndrome. Its lead candidates, ANAVEX 2-73 and ANAVEX 3-71, are in clinical development, with additional compounds in earlier-stage programs.